MRZM

Marizyme (QB) Stock Price

1.50
0.00 (0.0%)
1.50
Best deals to access real time data!
DDE w/Realtime (Monthly)
Monthly Subscription
for only
$34.10
Small Cap Pro
Monthly Subscription
for only
$49.05
Canna Trader Pro
Monthly Subscription
for only
$59.99
VAT not included
Company Name Stock Ticker Symbol Market Type
Marizyme Inc (QB) MRZM OTCMarkets Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Previous Close Last Traded
0.00 0.0% 1.50 0.00 0.00 0.00 1.50 16:19:24
Bid Price Ask Price Spread Spread % News
1.10 2.95 1.85 62.71% 2 -
Stock Trades Traded Volume Average Volume 52 Week Range
1 50 1,399 0.31 - 3.25
Last Trade Time Type Quantity Stock Price Currency
09:30:04 50 $ 1.50 USD

Marizyme (QB) Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 30.28M 20.18M 4.93M $ - $ - - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
130.00 $ - 0.00% - -

more financials information »

Marizyme (QB) News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical MRZM Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week1.852.491.502.32335-0.35-18.92%
1 Month2.002.491.502.05263-0.50-25.0%
3 Months1.662.500.561.352,462-0.16-9.64%
6 Months2.803.000.561.451,766-1.30-46.43%
1 Year0.31063.250.311.501,9641.19382.94%
3 Years0.01983.400.0150.183884420,8091.487,475.76%
5 Years0.113.400.0150.138655722,2611.391,263.64%

Marizyme (QB) Description

We are a biotechnology company with clinically tested and patented use of protease therapeutic platform for the treatment of acute ischemic stroke, acute myocardial infactions, deep vein thrombosis and chronic wounds and burns. We call our platform Krillase®. We are focused on bringing late stage biopharmaceutical products to market in the acute care space that have been undervalued or need experienced leadership to successfully commercialize. We expect to reduce investor risk by diversifying our product portfolio with late stage highly de-risked assets with competitive advantages in safety, efficacy, cost and ease of use. This approach will allow us to grow through multiple applications and drive value through diversity.


Your Recent History
USOTC
MRZM
Marizyme (..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.